Tuesday 14 July 2026

One To Watch

Enlaza Therapeutics

A USA-based biotech company developing the first covalent biologic platform.

Company Overview

Want to Update your Company's Profile?


Latest Enlaza Therapeutics News

Vertex teams with Enlaza to expand gene therapy options
3 September 2025
Enlaza Therapeutics raises $100 million in series A financing
1 May 2024
More Enlaza Therapeutics news >


Today's issue

Q32 Bio reports top-line results for bempikibart in alopecia areata
Biotechnology
Q32 Bio reports top-line results for bempikibart in alopecia areata
13 July 2026
Biotechnology
Eisai touts latest findings for etalanetug in Alzheimer's
13 July 2026
Pharmaceutical
Pfizer names Danna Breen to lead obesity discovery as Kendra Bence exits
13 July 2026
Biotechnology
Stoke Tx appoints Thomas McCauley as CSO
13 July 2026
Biotechnology
GSK posts positive interim results for Jemperli in rectal cancer
13 July 2026
Pharmaceutical
GHIT Fund commits $18 million to advance six global infectious disease R&D programs
13 July 2026
Biotechnology
Caixa Capital Risc rebrands as Criteria Capital Risc
13 July 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze